ATE187063T1 - Arzneimittel - Google Patents

Arzneimittel

Info

Publication number
ATE187063T1
ATE187063T1 AT95932166T AT95932166T ATE187063T1 AT E187063 T1 ATE187063 T1 AT E187063T1 AT 95932166 T AT95932166 T AT 95932166T AT 95932166 T AT95932166 T AT 95932166T AT E187063 T1 ATE187063 T1 AT E187063T1
Authority
AT
Austria
Prior art keywords
drug
Prior art date
Application number
AT95932166T
Other languages
English (en)
Inventor
Li Li-Bovet
Keith Arthur Johnson
Original Assignee
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc
Application granted granted Critical
Publication of ATE187063T1 publication Critical patent/ATE187063T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
AT95932166T 1994-09-28 1995-09-27 Arzneimittel ATE187063T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9419536A GB9419536D0 (en) 1994-09-28 1994-09-28 Medicaments

Publications (1)

Publication Number Publication Date
ATE187063T1 true ATE187063T1 (de) 1999-12-15

Family

ID=10762008

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95932166T ATE187063T1 (de) 1994-09-28 1995-09-27 Arzneimittel

Country Status (32)

Country Link
US (1) US5849265A (de)
EP (1) EP0783302B1 (de)
JP (1) JPH10506887A (de)
KR (1) KR100375469B1 (de)
CN (1) CN1084614C (de)
AP (1) AP742A (de)
AT (1) ATE187063T1 (de)
AU (1) AU707922B2 (de)
BG (1) BG62839B1 (de)
BR (1) BR9509108A (de)
CZ (1) CZ286356B6 (de)
DE (1) DE69513671T2 (de)
DK (1) DK0783302T3 (de)
EE (1) EE03380B1 (de)
ES (1) ES2140706T3 (de)
FI (1) FI971279L (de)
GB (1) GB9419536D0 (de)
GE (1) GEP20002140B (de)
GR (1) GR3032245T3 (de)
HU (1) HU221856B1 (de)
IS (1) IS1991B (de)
MD (1) MD1900C2 (de)
MX (1) MX9702149A (de)
NO (1) NO313658B1 (de)
NZ (1) NZ292995A (de)
OA (1) OA10603A (de)
PL (1) PL181453B1 (de)
RO (1) RO118564B1 (de)
RU (1) RU2157188C2 (de)
SK (1) SK281519B6 (de)
UA (1) UA47412C2 (de)
WO (1) WO1996009816A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9410222D0 (en) * 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
US6039932A (en) * 1996-09-27 2000-03-21 3M Innovative Properties Company Medicinal inhalation aerosol formulations containing budesonide
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
US6984404B1 (en) 1998-11-18 2006-01-10 University Of Florida Research Foundation, Inc. Methods for preparing coated drug particles and pharmaceutical formulations thereof
EP1169019B1 (de) * 1999-04-14 2003-02-26 Glaxo Group Limited Pharmazeutische aerosolformulierung
US6406745B1 (en) * 1999-06-07 2002-06-18 Nanosphere, Inc. Methods for coating particles and particles produced thereby
GB0009606D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
US6451287B1 (en) 2000-05-26 2002-09-17 Smithkline Beecham Corporation Fluorinated copolymer surfactants and use thereof in aerosol compositions
GB0016876D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Novel formulation
US6787532B2 (en) * 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6858593B2 (en) * 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
GB0019172D0 (en) * 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6858596B2 (en) * 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6750210B2 (en) * 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6777400B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
CA2417826A1 (en) * 2000-08-05 2002-02-14 Glaxo Group Limited 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
JP2004509159A (ja) 2000-09-22 2004-03-25 グラクソ　グループ　リミテッド 新規なアルカン酸誘導体
GB0106046D0 (en) 2001-03-12 2001-05-02 Glaxo Group Ltd Canister
UA77656C2 (en) * 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
AR033290A1 (es) * 2001-04-30 2003-12-10 Glaxo Group Ltd Derivados antiinflamatorios de androstano
EP1395604B1 (de) * 2001-06-12 2008-06-25 Glaxo Group Limited Neue anti inflammatorische 17.alpha.-heterozyklische ester von 17.beta.-carbothioat androstan derivativen
GB0118364D0 (en) * 2001-07-27 2001-09-19 Glaxo Group Ltd Compounds
CN1279893C (zh) * 2001-08-03 2006-10-18 葛兰素集团有限公司 表面活性剂化合物及其用途
GB0125127D0 (en) 2001-10-19 2001-12-12 Glaxo Group Ltd Compounds
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
JP2003221335A (ja) 2001-10-26 2003-08-05 Dey Lp 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法
US20030203930A1 (en) * 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
US20050175545A1 (en) * 2002-02-04 2005-08-11 Keith Biggadike Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
JP2005517701A (ja) * 2002-02-13 2005-06-16 グラクソ　グループ　リミテッド 界面活性剤として使用するためのカルボン酸化合物
GB0205327D0 (en) * 2002-03-06 2002-04-17 Glaxo Group Ltd compounds
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
JP4607112B2 (ja) 2003-08-11 2011-01-05 グラクソ グループ リミテッド 医薬定量噴霧式吸入器及び前記吸引器に関連する方法
AU2004270171A1 (en) 2003-08-29 2005-03-17 Glaxo Group Limited Pharmaceutical metered dose inhaler and methods relating thereto
US7030255B2 (en) * 2004-03-09 2006-04-18 Lyondell Chemical Technology, L.P. Oxidation process with in-situ H202 generation and polymer-encapsulated catalysts therefor
EP1949891A1 (de) 2004-10-12 2008-07-30 Generics (UK) Limited Verfahren zur Herstellung von Suspensionsaerosolformulierungen, wobei die Partikel durch Fällung im Innenkanister gebildet werden
WO2006040598A2 (en) * 2004-10-12 2006-04-20 Generics (Uk) Limited Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister
GB0507165D0 (en) * 2005-04-08 2005-05-18 Glaxo Group Ltd Novel crystalline pharmaceutical product
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
PL2425820T3 (pl) 2007-02-11 2015-08-31 Map Pharmaceuticals Inc Sposób terapeutycznego stosowania dhe w celu umożliwienia szybkiego złagodzenia migreny przy jednoczesnym zminimalizowaniu profilu działań niepożądanych
GB0712454D0 (en) * 2007-06-27 2007-08-08 Generics Uk Ltd Pharmaceutical compositions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5529524A (en) * 1978-08-21 1980-03-01 Toyo Aerosol Kogyo Kk Powdery aerosol composition
US4352789A (en) * 1980-03-17 1982-10-05 Minnesota Mining And Manufacturing Company Aerosol compositions containing finely divided solid materials
GB8501015D0 (en) * 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US4965066A (en) * 1989-06-06 1990-10-23 E. I. Du Pont De Nemours And Company Intranasal administration of 3,3-disubstituted indolines
ES2060184T3 (es) * 1989-06-22 1994-11-16 Atta Moleculas anfifilicas conteniendo fluor y fosforo con propiedades tensoactivas.
GB8921222D0 (en) * 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
IL97065A (en) * 1990-02-02 1994-01-25 Fisons Plc Repellent preparations for aerosol
DE4003272A1 (de) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
JPH05505824A (ja) * 1990-03-23 1993-08-26 ミネソタ　マイニング　アンド　マニュファクチャリング　カンパニー 所定投与量エアロゾル製剤の製造のための可溶性弗素界面活性剤の使用
AU650463B2 (en) * 1990-06-27 1994-06-23 Minnesota Mining And Manufacturing Company The use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
US5126123A (en) * 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations

Also Published As

Publication number Publication date
KR100375469B1 (ko) 2003-10-17
NZ292995A (en) 1998-10-28
MD970134A (en) 1999-02-28
PL319342A1 (en) 1997-08-04
BG62839B1 (bg) 2000-09-29
HU221856B1 (hu) 2003-02-28
MX9702149A (es) 1998-04-30
NO313658B1 (no) 2002-11-11
US5849265A (en) 1998-12-15
AP9700951A0 (en) 1997-04-30
AP742A (en) 1999-04-26
SK39397A3 (en) 1997-10-08
HUT77377A (hu) 1998-04-28
FI971279A0 (fi) 1997-03-26
CZ93697A3 (en) 1997-08-13
EP0783302B1 (de) 1999-12-01
OA10603A (en) 2002-08-30
MD1900C2 (ro) 2002-12-31
NO971422D0 (no) 1997-03-25
ES2140706T3 (es) 2000-03-01
GB9419536D0 (en) 1994-11-16
NO971422L (no) 1997-05-23
SK281519B6 (sk) 2001-04-09
AU707922B2 (en) 1999-07-22
FI971279A7 (fi) 1997-03-26
DE69513671D1 (de) 2000-01-05
UA47412C2 (uk) 2002-07-15
RU2157188C2 (ru) 2000-10-10
WO1996009816A1 (en) 1996-04-04
BG101347A (en) 1997-12-30
IS1991B (is) 2005-02-15
CN1084614C (zh) 2002-05-15
IS4438A (is) 1997-03-10
AU3532195A (en) 1996-04-19
CN1168630A (zh) 1997-12-24
FI971279L (fi) 1997-03-26
PL181453B1 (pl) 2001-07-31
DE69513671T2 (de) 2000-04-06
EE9700061A (et) 1997-08-15
EP0783302A1 (de) 1997-07-16
EE03380B1 (et) 2001-04-16
BR9509108A (pt) 1998-07-14
JPH10506887A (ja) 1998-07-07
GR3032245T3 (en) 2000-04-27
RO118564B1 (ro) 2003-07-30
CZ286356B6 (cs) 2000-03-15
KR970705981A (ko) 1997-11-03
DK0783302T3 (da) 2000-05-29
MD1900B2 (en) 2002-04-30
GEP20002140B (en) 2000-06-25

Similar Documents

Publication Publication Date Title
DE69513671D1 (de) Arzneimittel
ATE367150T1 (de) Arzneimittel
DE69629755D1 (de) Irbesartanhaltiges Arzneimittel
FI973243L (fi) Uusi farmaseuttinen yhdistelmä
FI970995L (fi) Farmaseuttisia yhdisteitä
FI971018L (fi) Farmaseuttisia yhdisteitä
DE69908021D1 (de) Ziprasidonhaltige Arzneimittel
DE69224656D1 (de) Arzneimittel
DE122010000011I1 (de) Flüssige gonadotropinhaltige Arzneimittel
NO20004345L (no) Farmasøytisk sammensetning
ID23874A (id) Obat
NO954486D0 (no) Farmasöytiske formuleringsgrunnlag
FI954243A7 (fi) Farmaseuttiset yhdisteet
BR9610214A (pt) Compostos farmacéuticos
BR9600809A (pt) Medicamento
BR9508339A (pt) Medicamento
FI953256L (fi) Hyperglykemian vastaisesti vaikuttava lääkeaine
BR9507768A (pt) Composição farmacêutica
ITMI941169A0 (it) Formulazioni farmaceutiche
FI955605A0 (fi) Aryloivia lääkkeitä
FI951155L (fi) Farmaseuttinen valmiste
NO965448D0 (no) Farmasöytiske forbindelser
DE59610423D1 (de) Partikulare arzneiform
FI950737L (fi) Lääkkeitä
DE59805373D1 (de) Nephroprotektive Arzneimittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee